Psoriasis with short stature improved by adalimumab

Area of Science:

• Pediatric Rheumatology
• Dermatology
• Endocrinology

Background:

• Psoriasis is a chronic inflammatory condition affecting children.
• Short stature in pediatric psoriasis is rarely reported, potentially linked to systemic inflammation.
• Biologic therapies offer targeted treatment for chronic inflammatory diseases.

Observation:

• A case study involving a child with psoriasis and subsequent short stature.
• The child experienced growth impairment following the onset of psoriasis.
• Psoriasis symptoms were present alongside growth concerns.

Findings:

• Treatment with adalimumab, a biologic agent, was administered.
• Adalimumab effectively managed the child's psoriasis symptoms.
• Significant improvement in the child's short stature was observed post-treatment.

Implications:

• Early biologic therapy, such as adalimumab, may be beneficial for pediatric psoriasis patients with short stature.
• Addressing systemic inflammation in pediatric psoriasis could improve growth outcomes.
• This case highlights a potential therapeutic approach for growth impairment associated with pediatric psoriasis.